These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
covid19.pdf (1022.67 kB)

N-ferrocenylmethyl-Derivatives As Spike Glycoprotein Inhibitors Of SARS-CoV-2 Using In Silico Approaches

submitted on 09.05.2020, 11:41 and posted on 12.05.2020, 07:24 by NADJIBA ZEGHEB, LANEZ Elhafnaoui, Touhami Lanez

Background and Objectives: By the end of 2019, a novel human coronavirus outbreak started in Wuhan and spread to the world becoming a global pandemic, patients were diagnosed with severe respiratory syndrome. Studies have shown that SARS-CoV2 interact with angiotensin-converting enzyme 2 (ACE2), its host cell receptor, by its Spike Glycoprotein. The aim of this study is to prevent this interaction by inhibiting Spike glycoprotein. Materials and Methods: The interaction of the Spike Glycoprotein of SARS-COV-2 extracted from protein data bank (PDB Code: 6VSB and 6LZG) with 10 different ferrocene derivatives ligands were investigated by performing docking studies using Autodock Tools 4.2. software. Results: The obtained results showed that N-ferrocenyl-methyl-3-nitroaniline was the best inhibitor ligand interacted with both proteins of coronavirus with the free binding energy equal to -5.38 and -6.65 Kcal/mol for 6VSB and 6LZG respectively with binding constant values equal to 8.7 × 103 and 72.72× 103respectively. Calculations revealed that the dominated mode of interaction for all the studied ligands with COVID-19 was the electrostatic mode via at least one H-bond and more than two hydrophobic Pi-Alkyl Bonds. Conclusion: Generally, the results indicated the existence of strong interactions between ligands and spike glycoprotein which prevent the virus to interact to ACE2 receptors.


Email Address of Submitting Author


university of eloued



ORCID For Submitting Author


Declaration of Conflict of Interest

The authors declare no conflict of interest